DaVita [DVA] vs HCA Healthcare [HCA] Detailed Stock Comparison
DaVita
NYSE
Loading...
HCA Healthcare
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: DaVita wins in 5 metrics, HCA Healthcare wins in 14 metrics, with 0 ties. HCA Healthcare appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | DaVita | HCA Healthcare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.74 | 14.99 | DaVita |
| Price-to-Book Ratio | 6.62 | -198.01 | HCA Healthcare |
| Debt-to-Equity Ratio | 742.20 | -105.85 | HCA Healthcare |
| PEG Ratio | 12.29 | 14.54 | DaVita |
| EV/EBITDA | 9.10 | 9.31 | DaVita |
| Profit Margin (TTM) | 6.63% | 8.21% | HCA Healthcare |
| Operating Margin (TTM) | 13.44% | 15.95% | HCA Healthcare |
| EBITDA Margin (TTM) | 13.44% | 15.95% | HCA Healthcare |
| Return on Equity | 54.79% | 13,631.68% | HCA Healthcare |
| Return on Assets (TTM) | 7.04% | 11.84% | HCA Healthcare |
| Free Cash Flow (TTM) | $1.47B | $5.64B | HCA Healthcare |
| Dividend Yield | N/A | 0.54% | N/A |
| 1-Year Return | -0.75% | 0.17% | HCA Healthcare |
| Price-to-Sales Ratio (TTM) | 0.81 | 1.18 | DaVita |
| Enterprise Value | $24.19B | $134.94B | HCA Healthcare |
| EV/Revenue Ratio | 1.87 | 1.86 | HCA Healthcare |
| Gross Profit Margin (TTM) | 30.52% | 84.91% | HCA Healthcare |
| Revenue per Share (TTM) | $156 | $293 | HCA Healthcare |
| Earnings per Share (Diluted) | $10.08 | $23.81 | HCA Healthcare |
| Beta (Stock Volatility) | 1.11 | 1.48 | DaVita |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
DaVita vs HCA Healthcare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| DaVita | -1.35% | -4.61% | -5.61% | -1.40% | -21.79% | -7.57% |
| HCA Healthcare | 0.84% | 6.77% | -8.36% | 4.06% | 6.78% | 19.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| DaVita | -0.75% | 61.62% | 68.12% | 70.92% | 335.33% | 496.38% |
| HCA Healthcare | 0.17% | 67.74% | 174.02% | 290.30% | 1,047.08% | 1,047.08% |
Performance & Financial Health Analysis: DaVita vs HCA Healthcare
| Metric | DVA | HCA |
|---|---|---|
| Market Information | ||
| Market Cap | $10.47B | $85.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 731,650 | 1,992,000 |
| 90 Day Avg. Volume | 798,900 | 1,613,657 |
| Last Close | $138.48 | $356.97 |
| 52 Week Range | $131.76 - $179.60 | $289.98 - $417.14 |
| % from 52W High | -22.90% | -14.42% |
| All-Time High | $179.60 (Jan 27, 2025) | $417.14 (Oct 14, 2024) |
| % from All-Time High | -22.90% | -14.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.06% |
| Quarterly Earnings Growth | -0.32% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.08% |
| Operating Margin (TTM) | 0.13% | 0.16% |
| Return on Equity (TTM) | 0.55% | 136.32% |
| Debt to Equity (MRQ) | 742.20 | -105.85 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-3.46 | $-18.16 |
| Cash per Share (MRQ) | $6.78 | $3.88 |
| Operating Cash Flow (TTM) | $2.34B | $11.93B |
| Levered Free Cash Flow (TTM) | $1.58B | $5.49B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.54% |
| Last 12-Month Dividend | N/A | $2.04 |
Valuation & Enterprise Metrics Analysis: DaVita vs HCA Healthcare
| Metric | DVA | HCA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.74 | 14.99 |
| Forward P/E | 12.29 | 14.54 |
| PEG Ratio | 12.29 | 14.54 |
| Price to Sales (TTM) | 0.81 | 1.18 |
| Price to Book (MRQ) | 6.62 | -198.01 |
| Market Capitalization | ||
| Market Capitalization | $10.47B | $85.88B |
| Enterprise Value | $24.19B | $134.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.87 | 1.86 |
| Enterprise to EBITDA | 9.10 | 9.31 |
| Risk & Other Metrics | ||
| Beta | 1.11 | 1.48 |
| Book Value per Share (MRQ) | $-3.46 | $-18.16 |
Financial Statements Comparison: DaVita vs HCA Healthcare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DVA | HCA |
|---|---|---|
| Revenue/Sales | $3.22B | $18.32B |
| Cost of Goods Sold | $2.24B | $2.76B |
| Gross Profit | $983.87M | $15.56B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $433.33M | $2.86B |
| EBITDA | $597.84M | $3.73B |
| Pre-Tax Income | $286.33M | $2.33B |
| Income Tax | $54.12M | $502.00M |
| Net Income (Profit) | $232.22M | $1.83B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DVA | HCA |
|---|---|---|
| Cash & Equivalents | $438.78M | $1.06B |
| Total Current Assets | $3.64B | $16.26B |
| Total Current Liabilities | $2.91B | $13.63B |
| Long-Term Debt | $11.72B | $42.92B |
| Total Shareholders Equity | $1.66B | $-438.00M |
| Retained Earnings | $1.70B | $-3.16B |
| Property, Plant & Equipment | $11.65B | $65.81B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DVA | HCA |
|---|---|---|
| Operating Cash Flow | $287.94M | $2.65B |
| Capital Expenditures | $-143.26M | $-991.00M |
| Free Cash Flow | $36.75M | $660.00M |
| Debt Repayment | $-345.97M | $-3.90B |
| Common Stock Repurchase | $-541.85M | $-2.51B |
Short Interest & Institutional Ownership Analysis
| Metric | DVA | HCA |
|---|---|---|
| Shares Short | 5.87M | 3.89M |
| Short Ratio | 6.89 | 2.67 |
| Short % of Float | 0.15% | 0.02% |
| Average Daily Volume (10 Day) | 731,650 | 1,992,000 |
| Average Daily Volume (90 Day) | 798,900 | 1,613,657 |
| Shares Outstanding | 80.54M | 249.98M |
| Float Shares | 38.08M | 169.07M |
| % Held by Insiders | 0.50% | 0.30% |
| % Held by Institutions | 0.48% | 0.66% |
Dividend Analysis & Yield Comparison: DaVita vs HCA Healthcare
| Metric | DVA | HCA |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.04 |
| Last 12-Month Dividend Yield | N/A | 0.54% |
| 3-Year Avg Annual Dividend | N/A | $2.29 |
| 3-Year Avg Dividend Yield | N/A | 0.22% |
| 3-Year Total Dividends | N/A | $6.88 |
| Ex-Dividend Date | N/A | Mar 17, 2025 |